Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes
Clinical trial NCT06403761 · COMPLETED
Trial details
- NCT number
- NCT06403761
- Sponsor
- Novo Nordisk A/S
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-06
- Primary completion
- 2025-12-28
- Enrollment
- 158
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.